Tempest reports 100% CR rate in 15 CAR-T-naïve patients across two Phase 1 trials of TPST-2003

Tempest Therapeutics, Inc.

100% complete response rate (CR) among all 15 CAR-T-naïve efficacy evaluable patients treated with TPST-2003 in two Phase 1 trials.
Favorable safety: no Grade >3 CRS or ICANS observed; 44 patients dosed across three studies to date.
Median progression-free survival of 23.1 months in rrMM patients, including those with extramedullary disease.
All 10 evaluable REDEEM-1 patients achieved CR per IMWG criteria; one prior BCMA CAR-T patient did not respond.
Company plans to meet with FDA later this year to discuss initiating a U.S. registrational study.

item 7.01 item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-26-207601
form_type: 8-K
ticker: TPST
cik: 0001544227
company_name: Tempest Therapeutics, Inc.
filed_at: 2026-05-06T23:59:59+00:00
discovered_at: 2026-05-14T18:02:32.449551+00:00
generated_at: 2026-05-14T22:37:57.012084+00:00
sec_items: ["7.01", "8.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.85
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-26-207601
json_url: https://secwatch.observer/filing/0001193125-26-207601.json
markdown_url: https://secwatch.observer/filing/0001193125-26-207601.md
text_url: https://secwatch.observer/filing/0001193125-26-207601.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1544227/000119312526207601/0001193125-26-207601-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1544227/000119312526207601/d93617d8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001193125-26-207601

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.